Amedica Corporation (NASDAQ:AMDA), a company that develops and commercializes silicon nitride ceramics as a biomaterial platform, is pleased to announce the release of its Scorpion™ articulating inserter to accompany the Valeo II™ TL interbody fusion device system. The Scorpion inserter will be commercially available mid-November 2015, and will aide in minimally-invasive transforaminal lumbar interbody fusion surgeries.
“The TLIF approach can be particularly complex, requiring superior surgeon expertise and precision,” said Dr. Sonny Bal, chairman and CEO of Amedica Corporation. “This articulating inserter, used with our Valeo II TL and Valeo II TL Round systems, offers greater control and placement accuracy for our silicon nitride interbody fusion device while performing this minimally-invasive technique. The release of Scorpion demonstrates our determination to enhance patient care through our proprietary material and innovative surgical solutions.”
The Valeo II TL and Valeo II TL Round are made of micro composite silicon nitride biomaterial, which offers a favorable environment for bone growth and osteointegration, when compared to competitive PEEK and titanium offerings. Valeo II silicon nitride interbody fusion devices are also semi-radiolucent with clearly visible boundaries in x-rays and produce no artifacts under MRI or CT scans. The combination of these properties is found only in Amedica’s silicon nitride biomaterial technology.
The Valeo II TL is indicated for intervertebral body fusion of the spine in skeletally mature patients and is designed for use with autograft to facilitate fusion. (Original Source)
Shares of Amedica closed today at $0.295, down -$0.011 or -3.44%. AMDA has a 1-year high of $3.43 and a 1-year low of $0.20. The stock’s 50-day moving average is $0.40 and its 200-day moving average is $0.41.
On the ratings front, Needham analyst Michael Matson maintained a Buy rating on AMDA, with a price target of $1, in a report issued on August 14. The current price target represents a potential upside of 244.8% from where the stock is currently trading. According to TipRanks.com, Matson has a total average return of 0.8%, a 55.9% success rate, and is ranked #1818 out of 3775 analysts.
Amedica Corporation is a commercial-stage biomaterial company. It is engaged in using its silicon nitride technology platform to develop, manufacture & commercialize medical devices. Its products include valeo interbody fusion devices & facet fixation.